Literature DB >> 27510870

[A retrospective study on the liver pathological characteristics and the effect of antiviral treatment for 1 to 7 years old children with heptitis B e antigen negative chronic hepatitis B].

S S Zhu1, Y Dong, L M Wang, Z Q Xu, D W Chen, Y Gan, F C Wang, J G Yan, L L Cao, P Wang, M Zhang, H F Zhang.   

Abstract

OBJECTIVE: To investigate the liver pathological characteristics and the clearance rate of hepatitis B surface antigen (HBsAg) with antiviral treatment for 1 to 7 years old children with heptitis B e antigen(HBeAg)-negative chronic hepatitis B.
METHOD: A total of 49 cases with HBeAg-negative chronic hepatitis B were treated with interferon (IFN) or IFN treatment for 6 months added with lamivudine, and were followed up for at least 6 months.Retrospective analysis was performed on the liver pathological characteristics, the efficacy of antivirus treatment and its influencing factors of the HBsAg clearance rate in the cases from June 2006 to December 2013 in the 302 Hospital of People's Liberation Army.The χ(2) test was used to compare the rates. RESULT: (1)The median age of cases was 3 years old(1-7 years old), 38 children were male(78%). Cases in the age group 1-2, >2 -3, >3 -4, >4-5, >5-6 and >6-7 were 7, 8, 14, 6, 6 and 8 respectively. HBsAg was 100% positive in mother of the cases. (2)There were 7 children whose pre-treatment alanine aminotransferase (ALT) were ≤80 U/L and pre-treatment ALT>200 U/L in 25 children. There were 24 children whose pre-treatment HBVDNA ≥1×10(7) U/ml. Genetype analysis was detected in 43 children, 3 children were B genotype, 38 were C genotype, 2 were B and C genotype. (3)Liver biopsy was performed in all children. The degree of liver inflammation ≥2 was seen in 48 (98%) children.Severe liver fibrosis and cirrhosis were found in 21(43%) children. (4)In the age group 1-2, >2-3, >3-4, >4-5, >5-6 and >6-7 years old , the clearance of HBsAg was 5, 6, 2, 1, 0 and 0 respectively. The HBsAg clearance rate between 1-3 years old group and 3-7 years old group has significant difference ((73%(11/15) vs. 9%(3/34), χ(2)=18.180, P=0.000). (5)The clearance of HBsAg in male group was 11, but 3 in female group.It showed no significant difference between two groups (χ(2)=0.073, P=0.787). (6) The clearance rate of HBsAg were 0, 24%(4/17) and 40%(10/25) in the groups of pre-treatment ALT ≤80 U/L, 80<ALT≤200 U/L and ALT >200 U/L, respectively. There were no significant difference between the groups of ALT≤200 U/L and ALT > 200 U/L(χ(2)=2.223, P=0.136). In the groups with pre-treatment HBV DNA <1×10(7)U/ml and HBV DNA≥1×10(7)U/ml, the clearance rate of HBsAg was 28%(7/25) and 29%(7/24). There were no significant elifference between two groups(χ(2)=0.008, P=0.928). (7)The clearance rate of HBsAg was 33%(7/21) in children with severe liver fibrosis and cirrhosis, while 25%(7/28) in children who had no severe liver fibrosis and cirrhosis.There were no significant difference between two groups(χ(2)=0.408, P=0.523).
CONCLUSION: There are obvious liver injuries and severe liver fibrosis in 1-7 years old children with HBeAg-negative chronic hepatitis B. The HBsAg clearance rate in the children with antiviral treatment correlated with age, among those who received antiviral treatment before 3 years old, the HBsAg clearance rate is relatively higher.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27510870     DOI: 10.3760/cma.j.issn.0578-1310.2016.08.006

Source DB:  PubMed          Journal:  Zhonghua Er Ke Za Zhi        ISSN: 0578-1310


  5 in total

1.  Diwu Yanggan capsule improving liver histological response for patients with HBeAg-negative chronic hepatitis B: a randomized controlled clinical trial.

Authors:  Hanmin Li; Zhihua Ye; Xiang Gao; Lisheng Zhang; Xin Yao; Jianxun Gu; Dingbo Lu; Ming Wan; Lin Xiao; Wangxi Cai; Xuesheng Yan; Binbin Zhao; Yu Wu; Jinrong Zhang
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

2.  Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.

Authors:  Yao Hu; Ying-Zi Ye; Li-Jing Ye; Xiao-Hong Wang; Hui Yu
Journal:  World J Pediatr       Date:  2019-09-05       Impact factor: 2.764

3.  Clinical Predictors of Functional Cure in Children 1-6 Years-old with Chronic Hepatitis B.

Authors:  Jing Pan; Haiyan Wang; Tiantian Yao; Xuejiao Liao; Hao Cheng; Suthat Liangpunsakul; Yan Wang; Min Zhang; Zheng Zhang
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

4.  Efficacy and safety of interferon alpha therapy in children with chronic hepatitis B: A long-term follow-up cohort study from China.

Authors:  Yao Hu; Yingzi Ye; Lijing Ye; Xiaohong Wang; Hui Yu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

5.  HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B.

Authors:  Chong Zhang; Zhengrong Yang; Ziyi Wang; Xiaoguang Dou; Qiuju Sheng; Yanwei Li; Chao Han; Yang Ding
Journal:  Int J Med Sci       Date:  2020-02-04       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.